Last Updated : April 27, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued Sort descending |
|---|---|---|---|---|---|---|
| Tagrisso | osimertinib | Non-small cell lung cancer | Active | |||
| N/A | Pembrolizumab | Melanoma (Skin) | Active | |||
| N/A | Nivolumab and Ipilimumab | Melanoma (Skin) | Active | |||
| Tafinlar-Mekinist | dabrafenib trametinib | Advanced or metastatic anaplastic thyroid cancer with BRAF V600E mutation | Pending | |||
| Ferinject | ferric carboxymaltose | Iron deficiency in adult patients with heart failure | Pending | |||
| Keytruda | Pembrolizumab | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | Not filed | |||
| Lynparza | Olaparib | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | Not filed | |||
| Adcetris | brentuximab vedotin | Hodgkin lymphoma | Withdrawn | |||
| Winlevi | clascoterone | Acne vulgaris | Withdrawn | |||
| Leqvio | inclisiran | Primary hypercholesterolemia | Active |
Last Updated : April 27, 2024